Cantargia receives Intention to grant notification from EPO for expanded patent protection in treatment of solid tumours
Cantargia AB announce that the European Patent Office (EPO) has issued an Intention to grant notification for the company’s divisional (second, follow-up) patent application regarding use of IL1RAP as a target for antibody therapy in solid tumours. The patent application has application number 15197139.7. Cantargia has previously received formal patent approval in Europe and other major territories for use of IL1RAP as target molecule for antibody therapy of several types of tumours.Cantargias lead project CAN04 (nidanilimab) is in clinical development, currently focused on treatment of non-